Published online Apr 28, 2022. doi: 10.35711/aimi.v3.i2.21
Peer-review started: December 16, 2021
First decision: January 26, 2022
Revised: February 12, 2022
Accepted: March 16, 2022
Article in press: March 16, 2022
Published online: April 28, 2022
Processing time: 133 Days and 0.6 Hours
Pancreatic adenocarcinoma remains to be one of the deadliest malignancies in the world despite treatment advancement over the past few decades. Its low survival rates and poor prognosis can be attributed to ambiguity in recommendations for screening and late symptom onset, contributing to its late presentation. In the recent years, artificial intelligence (AI) as emerged as a field to aid in the process of clinical decision making. Considerable efforts have been made in the realm of AI to screen for and predict future development of pancreatic ductal adenocarcinoma. This review discusses the use of AI in early detection and screening for pancreatic adenocarcinoma, and factors which may limit its use in a clinical setting.
Core Tip: Pancreatic adenocarcinoma has poor survival rate and high morbidity. Artificial intelligence is a potential tool to screen for high risk individuals and for early detection of pancreatic adenocarcinoma. Despite advances made in artificial intelligence research in pancreatic adenocarcinoma, it faces a number of challenges before it can be generalised and applied in a clinical setting.